Hostname: page-component-77c89778f8-gq7q9 Total loading time: 0 Render date: 2024-07-18T10:35:07.238Z Has data issue: false hasContentIssue false
  • English
  • Français

Second Generation Long-Acting Injectable Antipsychotics in Africa: About a Case

Published online by Cambridge University Press:  19 July 2023

J. Galvañ  and
F. R. Nguepy-Keubo
J. Galvañ*
Affiliation:
Department of Child and Adolescent Psychiatry, Institute of Psychiatry and Mental Health Hospital General Universitario Gregorio Marañón, Madrid, Spain
F. R. Nguepy-Keubo
Affiliation:
Hôpital Saint Vincent de Paul, Dschang, Cameroon
*
*Corresponding author.

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Introduction

Schizophrenia affects people worldwide. In Europe, the advantages of second-generation and long-acting injectable antipsychotics (SG-LAIs) are known and used, supported by scientific evidence. However, somewhere there is limited evidence on this topic.

Objectives

Highlight the improvements in antipsychotic treatment and raise awareness of the scar between Europe and Africa, showing the results of the evidence with a case of cooperation with Cameroon.

Methods

About a case of a 42-year-old Cameroonian woman with 25 years of schizophrenia, treated with first-generation antipsychotic polypharmacy (APP) oral and depot, with several psychotic relapses, disorganized behaviors, motor and cognitive impairment and isolation (telemedicine consultation received through a NGO platform).

A search on PubMed was performed, selecting two systematic reviews including “antipsychotic” AND “Africa”, one systematic review for SGAs and four reviews for LAIs.

Results

Seven articles were reviewed, finding that APP use is highly prevalent in Africa with a lack of research on this, SGAs show an improved safety and tolerability profile and LAIs are among the most effective treatments in psychiatry improving adherence and overall patient outcomes.

In our case, we recommend progressively adjusting treatment to SG-LAI monotherapy, visiting the patient six months later in Cameroon, observing sustained stability of positive symptoms with an improvement of negative symptoms and good adherence and tolerability to treatment without extrapyramidal effects.

Conclusions

Our case is an example of the evidence that supports the improvement that SG-LAIs represent in psychiatric treatment and how international cooperation can help bridge the gap between Africa and Europe. Nevertheless, more research is needed to build bridges.

Disclosure of Interest

None Declared

Type
Abstract
Information
European Psychiatry , Volume 66 , Special Issue S1: Abstracts of the 31st European Congress of Psychiatry , March 2023 , pp. S820
Creative Commons
Creative Common License - CCCreative Common License - BY
This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited.
Copyright
© The Author(s), 2023. Published by Cambridge University Press on behalf of the European Psychiatric Association
Submit a response

Comments

No Comments have been published for this article.